Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.
about
Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulenceCrystal Structures of Candida albicans Dihydrofolate Reductase Bound to Propargyl-Linked Antifolates Reveal the Flexibility of Active Site Loop Residues Critical for Ligand Potency and SelectivityCandida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005Epidemiology of invasive candidiasis: a persistent public health problemThe inositol regulon controls viability in Candida glabrataResults from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic locationCandidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links.Proteomic analysis of cytosolic proteins associated with petite mutations in Candida glabrata.Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.Candida infections and their prevention.Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit.Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).Spectrum and prevalence of fungi infecting deep tissues of lower-limb wounds in patients with type 2 diabetes.Risk factors for fluconazole-resistant Candida glabrata bloodstream infectionsAssimilation of NAD(+) precursors in Candida glabrata.Genome structure and dynamics of the yeast pathogen Candida glabrata.In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methodsMicroarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates.Evolutionary divergence in the fungal response to fluconazole revealed by soft clustering.Population structure and properties of Candida albicans, as determined by multilocus sequence typing.Canadian clinical practice guidelines for invasive candidiasis in adults.Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?Yarrowia lipolytica: safety assessment of an oleaginous yeast with a great industrial potential.Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingEpidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003.Candidemia in Norway (1991 to 2003): results from a nationwide studyCandida parapsilosis, an emerging fungal pathogenGlobal surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.Ibuprofen-mediated reversal of fluconazole resistance in clinical isolates of CandidaOptimization of 3-(phenylthio)quinolinium compounds against opportunistic fungal pathogens.Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp
P2860
Q27318203-CD50B4ED-D470-4481-B992-0F340C1D7E52Q27670663-D959458D-B5EA-43D2-BB67-A4A3CA05BFD9Q28260910-60925761-163F-40E2-B376-AF9F8019A89EQ29616758-ED5E641F-D440-414D-B769-F6EA7D926E44Q30048623-2CE65385-8D69-4D02-ADC1-DC99C26B5B1AQ30447051-CECDBCBA-C6F7-4E55-AF59-7594B7DA8C31Q30452976-D2A8E12E-0EDC-40AF-BC25-03F2D5D253BCQ33241991-A538C082-FF05-4B54-BBE1-A7F404C78EEAQ33750421-CFB023E8-2617-4546-9C12-BE4755DD1478Q33753405-E371A1D4-4E68-4870-A1D2-70DFD7EBC8CEQ33775256-D4936C14-992F-4FDB-B9E4-646DD2E3111BQ33806807-B4B2CFE0-12A2-4A28-A6A2-35C3424D0141Q33856434-20B2FB93-8203-4B63-B509-6F352300E388Q33859215-0E4075F5-AFFF-46F5-9749-13200884BBB5Q33909419-91FFFA81-9536-49C4-88C1-954010D3D408Q33932340-08D9399D-90E0-4A11-9195-A84F21615B2EQ34006001-5788DC98-8C82-48C8-96E8-69FBF04E5E0CQ34039890-0F21AB7F-C6FB-4B67-8B5C-13D6EBCA3F92Q34041745-8660DAE0-5DE2-4BF3-B89A-C93438FBD9B1Q34045265-EDFAFDCF-9369-469F-821C-439C86A381D4Q34080293-9AC0EF92-4304-4DA0-8731-9476F65075DEQ34143749-AA018227-E532-46AC-942A-E9C171469134Q34237335-AFC14544-784E-437C-9AD0-C3D2EDC960C9Q34332272-A53B108B-E5BB-4635-9EAD-72344E794479Q34431984-6F66A2A0-E391-457E-B2B7-9D9B9EF63759Q34459194-0FC5912C-CBC5-41A9-9FA2-C1A8ECF0614CQ34480715-A0274D61-759E-4610-ACB2-C599D39CB2E3Q34490092-2DA8EB94-1105-4814-9514-C07F6A9CE43AQ34620008-A98126F6-D6E8-43DF-8545-72144A73BFAFQ34647337-ED9A243B-930D-4F97-9B3E-482A11437D61Q34680777-41DEE1E3-A1FD-44DB-AD7D-03B54DE8A550Q34719299-AFEB8EF5-A178-4D76-9E59-1773D3BCB1A9Q34852747-BE2E7955-2B8B-42B4-B964-CED72F428AB0Q35073614-66F89E74-9D88-441F-A0F9-C9C417BFEFBEQ35139590-84E8E2BC-0B43-4E9E-B28F-467F0339A0DBQ35173074-CEEC88D4-DCFB-49E8-8BF1-62FB3A110F60Q35635693-7BF11C8F-8580-4930-9E4F-D79966D5605DQ35690728-B30DF46C-3CDF-46A6-84BC-F8FE0274BF94Q35714132-E17762CB-B563-443A-993D-BAE608F4E186Q35714264-0B3366A8-9D0A-4249-BC20-CD0C44866892
P2860
Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Twelve years of fluconazole in ...... oodstream isolates of Candida.
@ast
Twelve years of fluconazole in ...... oodstream isolates of Candida.
@en
type
label
Twelve years of fluconazole in ...... oodstream isolates of Candida.
@ast
Twelve years of fluconazole in ...... oodstream isolates of Candida.
@en
prefLabel
Twelve years of fluconazole in ...... oodstream isolates of Candida.
@ast
Twelve years of fluconazole in ...... oodstream isolates of Candida.
@en
P1476
Twelve years of fluconazole in ...... loodstream isolates of Candida
@en
P2093
International Fungal Surveillance Participant Group
M A Pfaller
P356
10.1111/J.1470-9465.2004.T01-1-00844.X
P478
10 Suppl 1
P577
2004-03-01T00:00:00Z